Skip to main content
. Author manuscript; available in PMC: 2008 May 15.
Published in final edited form as: Toxicol Appl Pharmacol. 2007 Feb 14;221(1):119–128. doi: 10.1016/j.taap.2007.02.003

Fig. 4.

Fig. 4

Stabilization of β-catenin protein levels by treatment with arsenite, antimonite or in the absence of insulin depends upon EGFR activation. (A) SIK cultures were treated as indicated starting at 90% confluence (day 0) followed by immunoblot analysis using ABC β-catenin, an antibody that detects the active, non-phosphorylated form. (B,C) SIK cultures were treated for 3 dyas with the indicated treatment followed by immunoblot analysis of total cell lysates with ABC β-catenin antibody or nuclear extracts with total β-catenin antibody. (D) Active β-catenin levels in hEp after 3 days of indicated treatment. β-Actin was used as a loading control.